|
Sep 6
|
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
|
|
Sep 3
|
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 29
|
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have earned a 26% CAGR over the last five years
|
|
Aug 21
|
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
|
|
Jun 11
|
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
|
|
May 7
|
Upgrade: Analysts Just Made A Massive Increase To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
|
|
May 6
|
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
|
|
May 6
|
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
|
|
May 4
|
Bicycle Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 2
|
Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress
|
|
May 2
|
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
|
|
Apr 24
|
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
|
|
Apr 2
|
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 5
|
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
|
|
Jan 22
|
15 Small-Cap Stocks with High Potential
|
|
Nov 30
|
Bicycle Therapeutics to Host R&D Day on December 14
|
|
Nov 7
|
Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Trimmed Their Revenue Forecasts By 13%
|
|
Nov 2
|
Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day
|
|
Nov 2
|
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
|
|
Nov 2
|
‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks
|